Triple-Negative PAM50 Non-Basal Breast Cancer Subtype Predicts Benefit from Extended Adjuvant Capecitabine

JUAN RAFAEL DE LA HABA RODRIGUEZ2026-01-292026-01-29202310.1158/1078-0432.CCR-22-21912-s2.0-85146365274https://www.scopus.com/inward/record.uri?eid=2-s2.https://ucocris.uco.es/handle/123456789/35941Cancer ResearchOncologyCancer ResearchOncologyTriple-Negative PAM50 Non-Basal Breast Cancer Subtype Predicts Benefit from Extended Adjuvant Capecitabineresearch article